Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis
- Conditions
- Mild Spinal Tuberculosis
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 300
- Registration Number
- NCT06917495
- Locations
- 🇨🇳
Shandong Public Health Clinical Center, Jinan, China
A PAN-USR TB Multi-Center Trial
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Shenzhen Third People's Hospital
- Target Recruit Count
- 610
- Registration Number
- NCT06905522
A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06835465
- Locations
- 🇺🇸
Fortrea Dallas CRU, Dallas, Texas, United States
Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride
- Conditions
- Interaction Drug Food
- Interventions
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Ahon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT06822166
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province), Jinan, Shandong, China
Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults
- Conditions
- Rifampicin-Resistant Pulmonary Tuberculosis Patients
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06701136
A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects
- Conditions
- Locally Advanced or Metastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 56
- Registration Number
- NCT06619951
- Locations
- 🇨🇳
Zhongda Hospital,Affiliated to Southeast University, Nanjing, Jiangsu, China
A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects
- Conditions
- Healthy Adult Subject
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Target Recruit Count
- 40
- Registration Number
- NCT06562088
- Locations
- 🇨🇳
The second hospital of anhui medical university, Hefei, Anhui, China
An Adaptive Trial to Find the Safest and Shortest TB Preventive Regimens.
- Conditions
- Tuberculosis Infection, Latent
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 1800
- Registration Number
- NCT06498414
- Locations
- 🇧🇯
Centre National Hospitalier Universitaire de Pneumo Phtisiologie de Cotonou (CNHU-PPC), Cotonou, Benin
🇧🇷Manaus, Manaus, Brazil
🇨🇦Unviversity of Calgary, Calgary, Alberta, Canada
A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06492525
- Locations
- 🇨🇳
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement
- Conditions
- Penile Prosthesis; Complications, Infection or InflammationErectile Dysfunction
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT06489431
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Uropartners Surgery Center, Des Plaines, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.